US20090312327A1 - Pyrrolidine derivatives as nk2 receptor antagonists - Google Patents

Pyrrolidine derivatives as nk2 receptor antagonists Download PDF

Info

Publication number
US20090312327A1
US20090312327A1 US12/482,490 US48249009A US2009312327A1 US 20090312327 A1 US20090312327 A1 US 20090312327A1 US 48249009 A US48249009 A US 48249009A US 2009312327 A1 US2009312327 A1 US 2009312327A1
Authority
US
United States
Prior art keywords
methyl
phenyl
pyrrolidin
dichloro
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/482,490
Other languages
English (en)
Inventor
Caterina Bissantz
Philippe Jablonski
Henner Knust
Andreas Koblet
Anja Limberg
Matthias Nettekoven
Hasane Ratni
Claus Riemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoffmann La Roche Inc
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BISSANTZ, CATERINA, JABLONSKI, PHILIPPE, KNUST, HENNER, KOBLET, ANDREAS, LIMBERG, ANJA, NETTEKOVEN, MATTHIAS, RATNI, HASANE, RIEMER, CLAUS
Assigned to HOFFMANN-LA ROCHE, INC. reassignment HOFFMANN-LA ROCHE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: F. HOFFMANN-LA ROCHE AG
Publication of US20090312327A1 publication Critical patent/US20090312327A1/en
Priority to US13/452,981 priority Critical patent/US8404679B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • NK2 receptors are found in the periphery and the central nervous system. In the periphery, the NK2 receptor is mainly found in the smooth muscle of the gastrointestinal, respiratory and urinary tracts. In the central nervous system, the presence of NK2 binding sites in the rat brain has been demonstrated in the hippocampus, thalamus and the septum. The presence of NK2 binding sites in several limbic regions suggest that NK2 receptors may modulate emotional processes. Based on this expression pattern, the therapeutic potential of several selective NK2 receptor antagonists has been investigated in animal models of anxiety and depression.
  • Saredutant (SR48968), a selective and brain penetrant NK2 receptor antagonist was effective in exploration based procedures sensitive to anxiolytics such as elevated plus maze and the light/dark test in rodents. Efficacy in procedures sensitive to anti-depressants in mouse, gerbils and marmosets is also been documented for Saredutant. Currently Saredutant is in clinical development for depression (Phase III).
  • NK2 receptor antagonists have potential as a new class of anti-depressants and anxiolytics.
  • NK2 receptor antagonists may be used in the treatment of schizophrenia.
  • the present invention provides compounds of formula I
  • the invention also provides pharmaceutical compositions containing compounds of formula I and methods for the manufacture of the compounds and compositions of the invention.
  • the present compounds are high potential NK-2 receptor antagonists for the treatment of depression and anxiety. Therefore, the invention further provides methods for the treatment of depression and anxiety.
  • lower alkyl denotes a straight- or branched-chain hydrocarbon group containing from 1-8 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like.
  • Preferred lower alkyl groups are groups with 1-4 carbon atoms.
  • lower alkyl substituted by halogen denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example —CF 3 , —CHF 2 , —CH 2 F, —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CF 2 CF 3 and the like.
  • Preferred lower alkyl substituted by halogen groups are groups having 1-4 carbon atoms.
  • lower alkoxy denotes an alkyl group as defined above, which is attached via an oxygen atom, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, i-butoxy, 2-butoxy, t-butoxy and the like.
  • Preferred alkoxy groups are groups with 1-4 carbon atoms.
  • lower alkoxy substituted by halogen denotes an alkoxy group as defined above wherein at least one hydrogen atom is replaced by halogen.
  • Preferred lower alkoxy substituted by halogen groups are groups having 1-4 carbon atoms.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • non aromatic heterocyclyl denotes a saturated cyclic ring containing from 5-7 ring atoms, wherein at least one of the ring atoms is heteroatom, selected from N, O and S, for example morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, and the like.
  • Preferred non aromatic heterocyclyl group is piperizinyl.
  • aryl denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 6-14 carbon atoms in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl or indanyl. Preferred is the phenyl group.
  • heteroaryl denotes a cyclic aromatic radical consisting of one or more fused rings containing 5-14 ring atoms, preferably containing 5-10 ring atoms, in which at least one ring is aromatic in nature and contains at least one heteroatom selected from N, O and S, for example quinoxalinyl, dihydroisoquinolinyl, pyrazinyl, pyrazolyl, pyridinyl, pyridyl, pyrimidinyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, furyl, imidazolyl, benzofuranyl, dihydrobenzofuranyl and benzo[1,3]dioxole.
  • Preferred heteroaryl group is pyridinyl, pyrazolyl, benzofuranyl, dihydrobenzofuranyl, benzo[1,3]dioxole,
  • “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
  • pharmaceutically acceptable acid addition salt embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
  • “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
  • a further embodiment of the invention are compounds of formula I-1
  • an embodiment of the present invention are compounds of formula I-11
  • R is hydrogen or lower alkyl
  • An embodiment of the present invention are further compounds of formula I-12
  • An embodiment of the present invention are further compounds of formula I-13
  • An embodiment of the present invention are further compounds of formula I-14
  • R 1 , n, and Ar are as described above for compounds of formula I-11.
  • An embodiment of the present invention are further compounds of formula I-15
  • R 1 , n, R′ and Ar are as described above for compounds of formula I-11.
  • An embodiment of the present invention are further compounds of formula I-16
  • the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods.
  • Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art.
  • the reaction sequence is not limited to the one displayed in scheme 1, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered.
  • Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
  • R 1 , R 2 , R 3 and Ar have the same meanings as described above.
  • the 3,4-disubstituted pyrrolidine IV is prepared via a stereo specific 1,3-dipolar cycloaddition between the 2-nitrostyrene derivative II and the azomethine ylide generated in situ from the N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine III in the presence of a catalytic amount of acid, such as TFA.
  • a catalytic amount of acid such as TFA.
  • the amino moiety is subsequently alkylated to produce VI.
  • R 1 , R 2 , R 3 and Ar have the same meanings as described above.
  • the secondary amine of the intermediates VI can be protected, for instance with a Boc group, followed by a selective debenzylation to produce IX. Then a coupling with a suitable carbamoyl chloride, acid chloride or carboxylic acid gives X. Deprotection with TFA affords the free amine XI, which after coupling with a carboxylic acid or acid chloride gives derivatives I.
  • the salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.
  • NK-2 receptor antagonists for the treatment of depression and anxiety.
  • the compounds were investigated in accordance with the tests given hereinafter.
  • hNK 2 receptor binding experiment were performed using [ 3 H]SR48968 (Catalog No. TRK398, specific activity: 27.0 Ci/mmol, Amersham, GE Healthcare UK limited, Buckinghamshire, UK) and membrane isolated from CHO cells stably expressing recombinant human NK2 receptor (product No. 6110510, Perkin Elmer biosignal Inc., Shelton, Conn., USA).
  • the membrane homogenates were centrifuged at 48,000 ⁇ g for 10 min at 4° C., the pellets were resuspended in the 50 mM Tris-HCl, 3 mM MnCl 2 , 4 ⁇ g/mL Chymostatin, 0.04% BSA binding buffer at pH 7.4 to a final assay concentration of 6.5 ⁇ g protein/well.
  • membranes were incubated with [ 3 H]SR48968 at a concentration equal to K D value of radioligand and 10 concentrations of the inhibitory compound (0.0003-10 ⁇ M) (in a total reaction volume of 500 ⁇ l) for 75 min at room temperature (RT).
  • membranes were filtered onto unitfilter (96-well white microplate with bonded GF/C filter preincubated 1 h in 0.3% polyethylenimine, Packard BioScience, Meriden, Conn.) with a Filtermate 196 harvester (Packard BioScience) and washed 4 times with ice-cold 50 mM Tris-HCl, pH 7.4 buffer.
  • Nonspecific binding was measured in the presence of 10 ⁇ M 1- ⁇ 2-[(R)-3-(3,4-dichloro-phenyl)-1-(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yl]-ethyl ⁇ -4-phenyl-piperidine-4-carboxylic acid amide.
  • the present invention also provides pharmaceutical compositions containing compounds of the invention, for example, compounds of formula I or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
  • Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions.
  • the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
  • compositions of the invention in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier.
  • suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic carriers. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatin capsules.
  • Suitable excipients for soft gelatin capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
  • Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
  • Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
  • Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
  • compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • the dosage at which compounds of the invention can be administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • a daily dosage of about 0.01 mg to about 1000 mg per day and person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
  • the active substance, lactose and corn starch were firstly mixed in a mixer and then in a comminuting machine. The mixture was returned to the mixer, the talc was added thereto and mixed thoroughly. The mixture was filled by machine into hard gelatin capsules.
  • the suppository mass was melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C. Thereupon, the finely powdered active substance was added thereto and stirred until it had dispersed completely. The mixture was poured into suppository moulds of suitable size, left to cool. The suppositories were then removed from the moulds and packed individually in wax paper or metal foil.
  • reaction mixture was stirred an additional 2 hours, concentrated under vacuo, and then filtrated on silica gel (CH 2 Cl 2 as solvent) to afford the intermediate rac-(3R,4S)-3-(3,4-dichloro-phenyl)-4-[(4-methoxy-3-trifluoromethyl-benzoyl)-methyl-amino]-pyrrolidine-1-carboxylic acid 2,2,2-trichloro-ethyl ester.
  • This intermediate was then dissolved in AcOH (10 ml) and zinc powder (300 mg) was added in 4 portions over 3 hours. The reaction mixture was then filtered on celite, concentrated under vacuo, taken up in CH 2 Cl 2 , and washed with aq. NaHCO 3 .
  • Titanium (IV) chloride (0.36 g, 1.89 mmol) was added drop wise to a suspension of zinc powder (0.25 g, 3.78 mmol) in THF (3 ml). This solution was heated at 68° C. for one hour, then cooled to RT before rac-(3R,4S)-1-benzyl-3-(4-chloro-phenyl)-4-nitro-pyrrolidine (0.20 g, 0.63 mmol) in THF (2 ml) was added. The reaction mixture was then stirred at reflux over night. The reaction was cooled to RT, diluted with 300 ml of Et 2 O, washed with an aqueous solution of NaHCO 3 and the organic phases were dried over Na 2 SO 4 .
  • Second step To a stirred solution of carbonic acid ditrichloromethyl ester (triphosgene) (560 mg, 1.88 mmol) in CH 2 Cl 2 (10 mL) at ⁇ 78° C., was added a solution of (S)-1-methanesulfonyl-2-methyl-piperazine (838 mg, 4.70 mmol) and pyridine (0.74 mL, 9.4 mmol) in CH 2 Cl 2 (10 mL) over 1 hour. The temperature was raised to RT, and stirring was continued over night. The organic phase was washed with H 2 O, dried over Na 2 SO 4 .
  • triphosgene triphosgene
  • Second step To a stirred solution of carbonic acid ditrichloromethyl ester (triphosgene) (1.17 g, 3.95 mmol) in CH 2 Cl 2 (20 mL) at ⁇ 78° C., was added a solution of (R)-1-methanesulfonyl-2-methyl-piperazine (1.76 g, 9.9 mmol) and pyridine (1.60 mL, 20 mmol) in CH 2 Cl 2 (20 mL) over 1 hour. The temperature was raised to RT, and stirring was continued over night. The organic phase was washed with H 2 O, dried over Na 2 SO 4 .
  • triphosgene triphosgene
  • N- ⁇ (3RS,4SR)-4-(4-Chloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -4-methoxy-N-methyl-3-trifluoromethyl-benzamide was subjected to column chromatography on chiral phase to yield N- ⁇ (3R,4S)-4-(4-chloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -4-methoxy-N-methyl-3-trifluoromethyl-benzamide (MS(m/e): 606.2 [M] + ) as a colorless oil and N- ⁇ (3S,4R)-4-(4-chloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-
  • step b the title compound [(3RS,4SR)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester was prepared from [(3RS,4SR)-1-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and was obtained as a light brown oil. MS m/e: 345.1 [M] + .
  • step c the title compound ⁇ (3RS,4SR)-4-(3,4-dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -methyl-carbamic acid tert-butyl ester was prepared from [(3RS,4SR)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and was obtained as a light brown foam. MS m/e: 538.3 [M] + .
  • N- ⁇ (3SR,4RS)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -4-methoxy-N-methyl-3-trifluoromethyl-benzamide was subjected to column chromatography on chiral phase to yield N- ⁇ (3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -4-methoxy-N-methyl-3-trifluoromethyl-benzamide (MS(m/e): 640.3 [M] + ) as a light brown oil and N- ⁇ (3R,4S)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4
  • N- ⁇ (3RS,4SR)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -2-(4-fluoro-phenyl)-N-methyl-acetamide was subjected to column chromatography on chiral phase to yield N- ⁇ (3R,4S)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)-piperidine-4-carbonyl]-pyrrolidin-3-yl ⁇ -2-(4-fluoro-phenyl)-N-methyl-acetamide (MS(m/e): 574.2 [M] + ) as a light brown oil and N- ⁇ (3S,4R)-4-(3,4-Dichloro-phenyl)-1-[1-(1-methyl-cyclopropanecarbonyl)
  • step a the title compound (3SR,4RS)-1-benzyl-3-(4-chloro-2-methyl-phenyl)-4-nitro-pyrrolidine was prepared from 4-chloro-2-methyl-1-((E)-2-nitro-vinyl)-benzene instead of 1,2-dichloro-4-((E)-2-nitro-vinyl)-benzene and was obtained as a light brown oil. MS m/e: 331.1 [M+H] + .
  • step b the title compound (3RS,4SR)-1-benzyl-4-(4-chloro-2-methyl-phenyl)-pyrrolidin-3-ylamine was prepared from (3SR,4RS)-1-benzyl-3-(4-chloro-2-methyl-phenyl)-4-nitro-pyrrolidine instead of (3SR,4RS)-1-benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine and was obtained as a light brown foam. MS m/e: 301.2 [M+H] + .
  • step c the title compound [(3RS,4SR)-1-benzyl-4-(4-chloro-2-methyl-phenyl)-pyrrolidin-3-yl]-methyl-amine was prepared from (3RS,4SR)-1-benzyl-4-(4-chloro-2-methyl-phenyl)-pyrrolidin-3-ylamine instead of (3RS,4SR)-1-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine and was obtained as a colorless oil. MS m/e: 315.1 [M+H] + .

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
US12/482,490 2008-06-16 2009-06-11 Pyrrolidine derivatives as nk2 receptor antagonists Abandoned US20090312327A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/452,981 US8404679B2 (en) 2008-06-16 2012-04-23 Pyrrolidine derivatives as NK2 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08158326 2008-06-16
EP08158326.2 2008-06-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/452,981 Continuation US8404679B2 (en) 2008-06-16 2012-04-23 Pyrrolidine derivatives as NK2 receptor antagonists

Publications (1)

Publication Number Publication Date
US20090312327A1 true US20090312327A1 (en) 2009-12-17

Family

ID=40843342

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/482,490 Abandoned US20090312327A1 (en) 2008-06-16 2009-06-11 Pyrrolidine derivatives as nk2 receptor antagonists
US13/452,981 Expired - Fee Related US8404679B2 (en) 2008-06-16 2012-04-23 Pyrrolidine derivatives as NK2 receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/452,981 Expired - Fee Related US8404679B2 (en) 2008-06-16 2012-04-23 Pyrrolidine derivatives as NK2 receptor antagonists

Country Status (13)

Country Link
US (2) US20090312327A1 (es)
EP (1) EP2297098A1 (es)
JP (1) JP2011524397A (es)
KR (1) KR20110010781A (es)
CN (1) CN102066321A (es)
AR (1) AR072118A1 (es)
AU (1) AU2009259493A1 (es)
BR (1) BRPI0914779A2 (es)
CA (1) CA2728054A1 (es)
IL (1) IL209266A0 (es)
MX (1) MX2010013311A (es)
TW (1) TW201002684A (es)
WO (1) WO2009153179A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152233A1 (en) * 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505173A (ja) * 2008-10-09 2012-03-01 エフ．ホフマン−ラ ロシュ アーゲー ピロリジンｎ−ベンジル誘導体
US20110144081A1 (en) 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
AU2012256237B2 (en) 2011-05-13 2017-01-05 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
WO2020107189A1 (en) * 2018-11-27 2020-06-04 Legion Pharma Co. Ltd Pyrrolidine compounds for the treatment of malaria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826858A (en) * 1984-12-21 1989-05-02 Boehringer Mannheim Gmbh N-substituted aziridine-2-carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US20090156572A1 (en) * 2007-12-03 2009-06-18 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ570100A0 (en) 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
KR101050700B1 (ko) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
AU2004277932B2 (en) * 2003-09-30 2009-07-16 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
EP1705176A4 (en) * 2004-01-14 2009-06-03 Takeda Pharmaceutical CARBOXYLAMIDE DERIVATIVE AND ITS USE
CN101061096A (zh) * 2004-11-22 2007-10-24 默克公司 环烷基酮基哌啶速激肽受体拮抗剂
CA2611550A1 (en) * 2005-06-27 2007-01-04 Merck & Co., Inc. Hydroisoindoline tachykinin receptor antagonists
WO2008021029A2 (en) * 2006-08-09 2008-02-21 Merck & Co., Inc. Process for making lactam tachykinin receptor antagonists
EP1975165A1 (de) * 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826858A (en) * 1984-12-21 1989-05-02 Boehringer Mannheim Gmbh N-substituted aziridine-2-carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US20090156572A1 (en) * 2007-12-03 2009-06-18 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
USRE48334E1 (en) 2008-09-19 2020-12-01 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
USRE49686E1 (en) 2008-09-19 2023-10-10 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US20110152233A1 (en) * 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds
JP2013514304A (ja) * 2009-12-18 2013-04-25 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−３受容体アンタゴニストとしてのピロリジン誘導体
RU2561271C2 (ru) * 2009-12-18 2015-08-27 Ф. Хоффманн-Ля Рош Аг Производные пирролидина в качестве антагонистов рецептора nk-3
US9346786B2 (en) 2009-12-18 2016-05-24 Hoffmann-La Roche Inc. Pyrrolidine compounds
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors

Also Published As

Publication number Publication date
CA2728054A1 (en) 2009-12-23
EP2297098A1 (en) 2011-03-23
CN102066321A (zh) 2011-05-18
BRPI0914779A2 (pt) 2015-10-20
MX2010013311A (es) 2010-12-21
US20120208803A1 (en) 2012-08-16
JP2011524397A (ja) 2011-09-01
KR20110010781A (ko) 2011-02-07
AR072118A1 (es) 2010-08-04
AU2009259493A1 (en) 2009-12-23
US8404679B2 (en) 2013-03-26
WO2009153179A1 (en) 2009-12-23
IL209266A0 (en) 2011-01-31
TW201002684A (en) 2010-01-16

Similar Documents

Publication Publication Date Title
US8404679B2 (en) Pyrrolidine derivatives as NK2 receptor antagonists
US8293770B2 (en) Pyrrolidine derivatives as NK-3 receptor antagonists
US7893062B2 (en) Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
US7812021B2 (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
US7528136B2 (en) Prolinamide derivatives as NK3 antagonists
JP2007522170A (ja) ケモカイン受容体アンタゴニスト
US8022099B2 (en) N-benzyl pyrrolidine derivatives
US20110152233A1 (en) Pyrrolidine compounds
US8618303B2 (en) Pyrrolidine derivatives
US7470684B2 (en) Spiropiperidine derivatives as NK3 antagonists
US8318749B2 (en) Quinazoline derivatives as NK3 receptor antagonists
US20110021565A1 (en) Piperidine derivatives as nk3 antagonists
US7501422B2 (en) Prolinamide-tetrazole derivatives as NK3 receptor antagonists
MXPA99005750A (es) Derivados novedosos de carboxamida ciclica substituida con carboxi

Legal Events

Date Code Title Description
AS Assignment

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BISSANTZ, CATERINA;JABLONSKI, PHILIPPE;KNUST, HENNER;AND OTHERS;REEL/FRAME:022986/0576

Effective date: 20090608

Owner name: HOFFMANN-LA ROCHE, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:022986/0656

Effective date: 20090609

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION